1
Kevin Rodzinak
Philip E Sanderson, Mark E Layton, Kevin J Rodzinak: Inhibitors of AKT activity. Merck Sharp & Dohme, Matthew A Leff, Yong Zhao, David A Muthard, May 1, 2012: US08168652 (3 worldwide citation)

The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt ...


2

3
Kevin Rodzinak
Jeannie M Arruda, Brian T Campbell, Nicholas D P Cosford, Jacob M Hoffman, Essa H Hu, Mark E Layton, Yiwei Li, Jun Liang, Kevin J Rodzinak, Tony Siu, Brian A Stearns, Lida R Tehrani, Mark T Bilodeau, Peter J Manley: Inhibitors of Akt activity. Merck Sharp & Dohme, Matthew A Leff, David A Muthard, March 22, 2011: US07910561 (1 worldwide citation)

The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer ...


4
Neville J Anthony, Robert P Gomez: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, December 29, 1998: US05854264 (85 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


5
Neville J Anthony: Biheteroaryl inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, December 29, 1998: US05854265 (83 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


6
Neville J Anthony, Terrence M Ciccarone, Christopher J Dinsmore, Robert P Gomez, Theresa M Williams, George D Hartman: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, January 5, 1999: US05856326 (82 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


7
Neville J Anthony, Robert P Gomez, Lekhanh O Tran, Steven D Young: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, July 25, 2000: US06093737 (72 worldwide citation)

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-prote ...


8
Victor M Garsky, Deborah Defeo Jones, Dong Mei Feng: Conjugates useful in the treatment of prostate cancer. Merck & Co, David A Muthard, Mark R Daniel, September 7, 1999: US05948750 (69 worldwide citation)

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertroph ...


9
Christopher J Dinsmore, Suzanne C MacTough, Gerald E Stokker, Theresa M Williams: Bisphenyl inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, January 20, 1998: US05710171 (63 worldwide citation)

The present invention comprises peptidomimetic compounds which comprise a suitably substituted aminoalkylbenzene and analine analogs, further substituted with a second phenyl ring attached via a bond, a heteroatom linker or an aliphatic linker. The instant compounds inhibit the farnesyl-protein tran ...


10
Neville J Anthony, Jeffrey M Bergman, Chrisopher J Dinsmore, Robert P Gomez, Suzanne C MacTough, Kelly M Solinsky, Theresa M Williams: Inhibitors of farnesyl-protein transferase. Merck & Co, David A Muthard, Mark R Daniel, May 26, 1998: US05756528 (53 worldwide citation)

The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. ...



Click the thumbnails below to visualize the patent trend.